Gout Therapeutic Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026
Global Gout Therapeutic Market is estimated to value over USD 2.8 billion by 2026 end and register a CAGR of over 8% during the forecast period 2019 to 2026.
Gout can be attributed
to the accumulation of uric acid in the human body. Uric acid creates crystals
in the joints, which will cause inflammation, followed by the pain of a gout
attack. When the level of uric acid rises, it will heighten the chances of gout
attacks.
The shifts in the
lifestyles of people has meant that there is a strong presence of gout on a
global scale. This has led to a sizeable global gout therapeutic market share.
Factors such as the exponential rise in kidney diseases, the volume of obesity
cases, the high levels of alcohol consumption, diets that are high in purine
and trends in the consumption of certain drugs namely diuretics will, in all
likelihood, fuel the global gout therapeutic market growth. Judging by market
analysis, the growing acceptance of biologics can be attributed to certain
features such as the potential to produce anti-inflammatory action that will be
instrumental in the augmentation of the global gout therapeutic market size. In
addition, there are certain drugs which are undergoing clinical tests and the
introduction of such drugs is anticipated to gain significant traction in the market.
However, issues such as stringent guidelines and patent expiry of certain drugs
may prove to be potentially detrimental to the global market.
Drugs such as
corticosteroids and NSAIDs count as some of the regulated and sanctioned drugs
in the treatment of gout illness and are easily acquired over the counter. Such
drugs are found to act positively in the gout condition and are registered to
exhibit robust growth in the gout therapeutic market. Furthermore, opting for
combination therapies because of the speedy treatment process as well as
reduced side effects are factors which are projected to advance the market
growth.
It has been observed
that manufacturers are allowing for implementation of strategies such as
collaborations and acquisitions as well as innovations in new products. Such
strategies are undertaken to meet the needs of the extensive volume of
patients. The regions of North America and Europe that are in control of the
global market for gout therapeutics, owing to the progressive developments in
pharmaceutical research. North America counts as one of the key players in this
market, in part, because of the rise in the level of geriatric population. In
addition, the US dominates a great deal of the market share across North
America. As a result of the rise in regional awareness regarding the disease,
the region of Asia Pacific is estimated to experience a large growth spur over
the forecast time frame.
Some companies which
have been making strides in the gout therapeutic market is Ironwood Pharmaceuticals,Inc.
They have launched an oral treatment known as Duzallo, for hyperuricemia that
is linked with gout in patients who have not been able to acquire the
anticipated levels of serum uric acid with a medically adequate dosage of
allopurinol.
Other such companies
include HemoShear Therapeutics, LLC, and Horizon Pharma plc have begun a
collaboration with an objective to introduce new gout therapeutics. Their
endeavors also include offering adequate treatment methods for gout, as well as
that of uncontrolled gout. HemoShear Therapeutics, LLC, observes biological
targets and facilitates drug programs in the treatment of metabolic disorders
with considerable unaddressed patient needs. HemoShear’s endeavor known as
‘Reveal-Tx’, allows for HemoShear to establish an efficient human disease model
to investigate the dynamics of disease and accordingly, utilize those
discoveries by testing and treating drug candidates, which, in turn, will
predict which drug will be suitable and treats the patients successfully.
HemoShear’s drug discovery program place emphasis on methylmalonic acidemias,
nonalcoholic steatohepatitis (NASH) and propionic.
Major players who are controlling this market includes Teijin
Pharma Limited, Horizon Pharma plc, Novartis AG, Merck & Co. Inc., Ironwood
Pharmaceuticals, Inc., Grunenthal Group, JW Pharmaceutical, Takeda
Pharmaceutical Company Limited, Selecta Biosciences, Inc., AstraZeneca,
Regeneron Pharmaceuticals, Inc
Request a Sample
Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=3485&page=requestsample
Global Gout Therapeutic Market Segmentation:
By
Component
- Colchicine
- Antihyperuricemic
agents (Urate-Lowering Drugs)
- Non-steroidal
Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Biologic
Response Modifiers (Biologics)
By
Distribution Channel
- Hospital
Pharmacy
- Retail
Pharmacy
- Online
Pharmacy
By
Region
- Europe
- North America
- Asia
Pacific
- Latin
America
- Middle
East & Africa
Purchase
a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=3485&page=askfordiscount
FutureWise
Key Takeaways:
- Growth prospects
- SWOT analysis
- Key trends
- Key data-points affecting market growth
Objectives
of the Study:
- To provide with an exhaustive analysis on the
global gout therapeutic market by component, by distribution channel, and
by region
- To cater comprehensive information on factors
impacting market growth (drivers, restraints, opportunities, and
industry-specific restraints)
- To evaluate and forecast micro-markets and the
overall market
- To predict the market size, in key regions (along
with countries)— North America, Europe, Asia Pacific, Latin America and Middle
East & Africa
- To record evaluate and competitive landscape
mapping- product launches, technological advancements, mergers and
expansions
We specialise
in high-growth niche markets, assuring flexibility, agility and customised
solutions for our clients. Through in-depth market insights and consultancy, we
present our clients with the tools they need to be at the forefront of their
industry – a position secured for far more than the near future.
Contact Us:
Company
Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: sales@futurewiseresearch.com
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com
Contact Person: Vinay Thaploo
Email: sales@futurewiseresearch.com
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com
Comments
Post a Comment